



Recruitment Completed in VF00102

Brisbane, Australia 16th July 2018: Factor Therapeutics Limited (ASX: FTT, the “Company”), an Australian biomedical company developing therapeutics for advanced wound care, is pleased to announce that recruitment into the Company’s Phase 2 clinical trial VF00102 is complete.

“We’re delighted to confirm that our final patient was randomised into the study last Friday. Thanks to a particularly strong performance in the last two months, we recruited a total of 156 patients, which is at the higher end of the target range set out in the revised trial analysis plan,” said Dr Ros Wilson, CEO of Factor Therapeutics.

“We are grateful to all of the patients, site staff and partners who have helped bring the trial to this key milestone and look forward to sharing top-line efficacy results in just over three months’ time,” added Dr Wilson.

Dr Cherrell Hirst, Chairman of Factor Therapeutics said, “I must congratulate Ros and her team for the level of focused effort they have demonstrated in completing recruitment for this trial in this time frame. This achievement creates confidence that in the event of a positive trial result, we can successfully execute our longer-term strategy.”

-ENDS-

Contact for Further Information:

Dr. Rosalind Wilson

Chief Executive Officer

Factor Therapeutics Limited

r.wilson@factor-therapeutics.com

About Factor Therapeutics

Factor Therapeutics Limited (“Factor”) is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF-001) in Phase II for the treatment of venous leg ulcers (VLUs). The company is also developing solutions for a variety of interventional wound care and serious orphan dermatology conditions. The company’s platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), Australia. Factor’s shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit <https://factor-therapeutics.com>